Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Radiopharm Theranostics Limited ( (AU:RAD) ) has provided an announcement.
Radiopharm Theranostics Limited announced its participation in the B. Riley Securities Precision Oncology & Radiopharma Investor Conference in New York on 28 February 2025. This event will feature over 35 biopharma and med-tech companies, providing Radiopharm an opportunity to present its innovative oncology solutions to a mix of institutional and professional investors, potentially enhancing its industry positioning and stakeholder engagement.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company that develops innovative radiopharmaceutical products for diagnostic and therapeutic applications in oncology. The company focuses on areas of high unmet medical need and has been listed on the ASX since November 2021 and on the Nasdaq since November 2024. Radiopharm’s pipeline includes peptides, small molecules, and monoclonal antibodies for cancer treatment, with ongoing Phase II and Phase I trials targeting various solid tumor cancers.
YTD Price Performance: 4.17%
Average Trading Volume: 10,333,648
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$58.35M
Find detailed analytics on RAD stock on TipRanks’ Stock Analysis page.
